ORPHA:26348
Acquired prothrombin deficiency
Also known as: Acquired hypoprothrombinemia
Publications
76
42.7th percentile
Trials
0
Interventional, condition-specific
Researchers
372
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare hemorrhagic disorder characterized by decreased factor II plasma levels in association with severe liver disease, vitamin K deficiency, or vitamin K antagonist treatment, or in the context of other conditions such as systemic lupus erythematosus, primary antiphospholipid syndrome, or infections. Patients present with increased bleeding tendency leading to easy bruising, frequent nosebleeds, hemorrhaging after surgery or trauma, and heavy menstrual bleeding, among others. Joint bleeding is uncommon.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016990
- MeSH:C538174
- UMLS:C0392610
- NCIT:C131622
Additional Mondo synonyms (2)
acquired hypoprothrombinemia · acquired prothrombin deficiency
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
76 matched papers (34 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
76
76 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
76 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
34 in the last 10 years · high confidence · 42.7th percentile (publications denominator)
Phrase hits: 76 · MeSH hits: 0
Who's working on it?
372
Distinct author names in 76 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Abuzaid H2 papers · 2024
Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 17138, Jordan.
Papers in Europe PMC - 02Bajaj SP2 papers · 1985Papers in Europe PMC
- 03Chen X2 papers · 2025
Department of Cardiology, Qingdao Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Papers in Europe PMC - 04Forastiero R2 papers · 2012
Department of Physiology, Favaloro University, Division of Hematology, Thrombosis and Haemostasis, University Hospital, Favaloro Foundation, Buenos Aires, Argentina. rforastiero@favaloro.edu.ar
Papers in Europe PMC - 05Herbst KD2 papers · 1985Papers in Europe PMC
- 06Ieko M2 papers · 2021
Department of Internal Medicine, School of Dentistry, Health Sciences University of Hokkaido, Tobetsu, Japan
Papers in Europe PMC - 07Ishiguro A2 papers · 2021
Center for Postgraduate Education and Training, National Center for Child Health and Development, NCCHD, Tokyo, Japan.
Papers in Europe PMC - 08Li Y2 papers · 2025
State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing 210009, P. R. China.
Papers in Europe PMC - 09Rapaport SI2 papers · 1985Papers in Europe PMC
- 10Xu X2 papers · 2025
Department of Cardiology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category prothrombin deficiency also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: prothrombin deficiency
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 9 · after dedupe 9 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 9 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (9)
- isrctn·ISRCTN55521313·Recruiting·A clinical trial looking at the effectiveness and safety of a human plasma-derived antithrombin called Atenativ, for patients who are resistant to heparin (a blood thinner) and are undergoing cardiac surgery with cardiopulmonary bypass
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13973041·No longer recruiting·Four-factor prothrombin complex concentrates outcomes in surgery and major bleed
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN66310879·No longer recruiting·A first-in-human study of HMB-001 in patients with Glanzmann thrombasthenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12348610·No longer recruiting·Safety and effectiveness of WF10 for diabetes-related blood vessel diseases
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16338908·No longer recruiting·Patients with congenital antithrombin deficiency undergoing a pharmacokinetic assessment, surgery or giving birth are treated with Atenativ, an antithrombin concentrate
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18138369·No longer recruiting·Comparing two different regimens of radiotherapy, combined with durvalumab immunotherapy and chemotherapy, in improving the response of rectal cancer to treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13751862·No longer recruiting·Assessment of venetoclax in combination with Ibrutinib in patients with Chronic Lymphocytic Leukaemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73545489·No longer recruiting·Trial to evaluate tranexamic acid therapy in thrombocytopenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN29749408·No longer recruiting·'SPOT Sign' seLection of Intracerebral haemorrhage to Guide Haemostatic therapy
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Acquired prothrombin deficiency — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Acquired prothrombin deficiency" OR "Acquired hypoprothrombinemia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Acquired prothrombin deficiency" OR "Acquired hypoprothrombinemia"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"prothrombin deficiency"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T23:20:35.004Z